Skip to main content
. 2021 May 31;18(8):2067–2068. doi: 10.1038/s41423-021-00702-y

Fig. 1. Timeline of some key discoveries and advances related to PD-L1 in antitumor immunity.

Fig. 1

Blue boxes represent critical studies or advances related to PD-L1. PD-L1 programmed cell death 1 ligand 1, FDA the Food and Drug Administration, NK cells natural killer cells